{"title":"Nanomedicines modulate the tumor immune microenvironment for cancer therapy.","authors":"Po-Han Chao, Vanessa Chan, Shyh-Dar Li","doi":"10.1080/17425247.2024.2412245","DOIUrl":"10.1080/17425247.2024.2412245","url":null,"abstract":"<p><strong>Introduction: </strong>In recent years, the evolution of immunotherapy as a means to trigger a robust antitumor immune response has revolutionized cancer treatment. Despite its potential, the effectiveness of cancer immunotherapy is hindered by low response rates and significant systemic side effects. Nanotechnology emerges as a promising frontier in shaping the future of cancer immunotherapy.</p><p><strong>Areas covered: </strong>This review elucidates the pivotal role of nanomedicine in reshaping the immune tumor microenvironment and explores innovative strategies pursued by diverse research groups to enhance the therapeutic efficacy of cancer immunotherapy. It discusses the hurdles encountered in cancer immunotherapy and the application of nanomedicine for small molecule immune modulators and nucleic acid therapeutics. It also highlights the advancements in DNA and mRNA vaccines facilitated by nanotechnology and outlines future trajectories in this evolving field.</p><p><strong>Expert opinion: </strong>Collectively, the integration of nanomedicine into cancer immunotherapy stands as a promising avenue to tackle the intricacies of the immune tumor microenvironment. Innovations such as immune checkpoint inhibitors and cancer vaccines have shown promise. Future developments will likely optimize nanoparticle design through artificial intelligence and create biocompatible, multifunctional nanoparticles, promising more effective, personalized, and durable cancer treatments, potentially transforming the field in the foreseeable future.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1719-1733"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yutong Zhao, Jingqi Sun, Xiao-Ling Xu, Jin Su, Yong-Zhong Du
{"title":"The potential of nanosystems in disrupting adenosine signaling pathways for tumor immunotherapy.","authors":"Yutong Zhao, Jingqi Sun, Xiao-Ling Xu, Jin Su, Yong-Zhong Du","doi":"10.1080/17425247.2024.2417687","DOIUrl":"10.1080/17425247.2024.2417687","url":null,"abstract":"<p><strong>Introduction: </strong>Adenosine (ADO) is a naturally occurring nucleoside primarily synthesized through the hydrolysis of extracellular adenosine triphosphate. Within the tumor microenvironment, ADO levels substantially increase, resulting in suppressed immune responses.</p><p><strong>Areas covered: </strong>Nanosystems offer a promising approach for precise drug delivery to tumor lesions. In this review, we provide an overview of the current research progress in the development of nanosystems that modulate adenosine signaling for tumor immunotherapy. These nanosystems are designed to target adenosine-hydrolyzing proteins, increase adenosine decomposition, and antagonize adenosine receptors.</p><p><strong>Expert opinion: </strong>Based on the literature review, adenosine has great potential in tumor immunotherapy, and nano-drug delivery system has great application prospects in targeted cancer therapy in the near future due to its superior characteristics.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1755-1770"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Future clinical potential of leukocyte-mimicking nanoparticles.","authors":"Francesca Taraballi","doi":"10.1080/17425247.2024.2430389","DOIUrl":"10.1080/17425247.2024.2430389","url":null,"abstract":"","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1697-1699"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Velmurugan Kailasam, Samhita Sai Veda Koduganti, Oindrilla Dasgupta, Prashant Garg, Jayabalan Nirmal
{"title":"Ocular delivery of Amphotericin B: current challenges and future perspectives.","authors":"Velmurugan Kailasam, Samhita Sai Veda Koduganti, Oindrilla Dasgupta, Prashant Garg, Jayabalan Nirmal","doi":"10.1080/17425247.2024.2420750","DOIUrl":"10.1080/17425247.2024.2420750","url":null,"abstract":"<p><strong>Introduction: </strong>Amphotericin B is a polyene antibiotic that is used as an off-label eye drop to treat fungal keratitis. Poor solubility, permeability and high susceptibility to hydrolytic degradation make it challenging to formulate a drug delivery system. Despite its drawbacks, it is a potent antifungal drug against Candida and other fungal species. However, it has not been explored much in ocular drug delivery. Hence, this review brings into focus the potential and increasing significance of Amphotericin B in ocular drug delivery.</p><p><strong>Areas covered: </strong>In this review, we have systematically summarized the use of Amphotericin B in ocular diseases, the various formulation challenges for Amphotericin B, along with its off-label ocular usage, and stability concerns. The degradation mechanism of Amphotericin B in different conditions was discussed in this article as well.</p><p><strong>Expert opinion: </strong>In the last few decades, several nanocarriers have been explored to improve the formulation challenges associated with Amphotericin B. Also, due to insufficient clinical studies and unknown toxicity profile, there is no US Food and Drug Administration (FDA) approved Amphotericin B formulation for ocular drug delivery. This review aims to offer thorough information about Amphotericin B in ocular drug delivery.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1793-1805"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Acceptability of Cyltezo pen among biologics autoinjector patients, autoinjector naïve patients, and healthcare professionals.","authors":"Raul Perez, Julie D Suman, Joe Reynolds","doi":"10.1080/17425247.2024.2394112","DOIUrl":"10.1080/17425247.2024.2394112","url":null,"abstract":"<p><strong>Background: </strong>Cyltezo® (Adalimumab-adbm) is an FDA-approved interchangeable biosimilar for Humira® (adalimumab reference product [RP]) that helps treat chronic inflammatory conditions. Adalimumab-adbm is administered via an autoinjector, the adalimumab-adbm pen. This study assessed user opinions related to usability, perceptions, convenience, safety features, and acceptability of the adalimumab-adbm pen.</p><p><strong>Methods: </strong>Ninety-eight Humira Pen users, 100 biologics pen naïve patients, and 99 healthcare professionals simulated the use of the adalimumab-adbm pen on injection pads. Opinions were captured with a validated questionnaire using Likert-type scales during moderated interviews. Binomial tests were conducted for top-two rating percentages.</p><p><strong>Results: </strong>Nearly 90% of participants found the adalimumab-adbm pen 'easy' or 'very easy' to use, handle, and learn how to use. Almost 90% of volunteers thought the pen was 'very' or 'extremely' solid and convenient to use at home. Around 80% found the pen to be 'very' or 'extremely' comfortable. Over 90% of respondents said they would be 'satisfied' or 'very satisfied' with the safety features and the device itself. Nearly 90% of respondents indicated being 'very' or 'extremely' open to adopting the adalimumab-adbm pen.</p><p><strong>Conclusions: </strong>The adalimumab-adbm pen provided users with a positive experience with features that benefit perceptions of usability, handling, safety, convenience, and acceptability.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1879-1888"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minkyung Kim, Geonwoo Kang, Hye Su Min, Youjin Lee, Shinyoung Park, Hyungil Jung
{"title":"Evolution of microneedle applicators for vaccination: the role of the latch applicator in optimizing dissolving microneedle-based immunization.","authors":"Minkyung Kim, Geonwoo Kang, Hye Su Min, Youjin Lee, Shinyoung Park, Hyungil Jung","doi":"10.1080/17425247.2024.2422939","DOIUrl":"10.1080/17425247.2024.2422939","url":null,"abstract":"<p><strong>Introduction: </strong>Dissolving microneedles (DMN) offer advantages in vaccine delivery, such as enhanced immunogenicity and simplified administration, by targeting immune-rich layers of the skin. However, these benefits require precise and consistent delivery, which poses practical challenges. To address this, specialized applicators are essential for ensuring the accurate deployment of DMNs, making this technology a viable alternative to traditional methods, particularly in low- and middle-income countries (LMICs), where healthcare infrastructure is limited.</p><p><strong>Areas covered: </strong>In this review, we examine the advancements in DMN-based vaccination and applicator design, focusing on their joint effort. These innovations have improved the precision and efficiency of DMN vaccine delivery. Complex and costly early-stage applicators have evolved into simpler and more cost-effective designs. We highlight these developments in this review, with the latch applicator as a key example of a feature that enhances vaccine delivery.</p><p><strong>Expert opinion: </strong>Although applicator development has advanced DMN-based vaccination toward practical use, challenges remain. Key areas for further optimization include user friendliness, cost, packaging volume, and wear time. Once optimized, DMN vaccination may become a highly effective and accessible tool for global immunization, supporting efforts to achieve worldwide vaccine equality.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1823-1835"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Suprachoroidal drug delivery: a versatile therapeutic platform.","authors":"Thomas A Ciulla, Emmett T Cunningham","doi":"10.1080/17425247.2024.2435461","DOIUrl":"10.1080/17425247.2024.2435461","url":null,"abstract":"","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1705-1713"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142786972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Are membrane-interacting peptides viable as excipients for non-injectable peptide delivery?","authors":"Hanne Mørck Nielsen","doi":"10.1080/17425247.2024.2435455","DOIUrl":"10.1080/17425247.2024.2435455","url":null,"abstract":"","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1715-1718"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pjotr Tinke, Wendy van Beurden, Martijn Goosens, Job van der Palen
{"title":"A randomized crossover study assessing critical errors, preferences, and ease of use of two multidose powder inhalers.","authors":"Pjotr Tinke, Wendy van Beurden, Martijn Goosens, Job van der Palen","doi":"10.1080/17425247.2024.2416511","DOIUrl":"10.1080/17425247.2024.2416511","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of inhaled medications in asthma and COPD is significantly impacted by inhalation errors. Feedback mechanisms, built into the design of the inhaler might reduce the number of critical errors. This study compares critical errors, preferences, and ease of use of two dry powder inhalers, the Nexthaler, and the Turbuhaler.</p><p><strong>Research design and methods: </strong>In this multi-center, prospective, randomized, open-label, cross-over study, the proportions of asthma and COPD patients making critical errors were compared between the Nexthaler and Turbuhaler after 4 weeks of clinical use, after having been trained for the correct use of both inhalers.</p><p><strong>Results: </strong>Ninety and 49 patients with asthma and COPD, respectively, were assessed. No significant difference was found in the number of critical errors between the two inhalers (3 with Nexthaler and 5 with Turbuhaler). However, more patients preferred the Nexthaler (57.6%) over the Turbuhaler (34.5%) (<i>p</i> = 0.006), while 7.9% stated no preference.</p><p><strong>Conclusions: </strong>The study found no significant differences in critical error rate between the Nexthaler and Turbuhaler but the Nexthaler was preferred over the Turbuhaler. This study highlights the importance of dedicating sufficient time to instructing patients on the correct inhalation technique, which can lead to long-term retention of the inhalation technique.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1889-1896"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}